Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imagabalin + lithium
- Development stage
- Unknown
- Lead developer
- Alzamend Neuro
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Imagabalin + lithium** is an unbranded combination drug consisting of **imagabalin** (a gabapentinoid) and **lithium** (a mood stabilizer). Imagabalin, structurally and mechanistically similar to pregabalin, acts as a ligand at the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Lithium is primarily used in bipolar disorder, functioning to stabilize mood by influencing neuronal sodium transport and modulating neurotransmitter availability. Although no clinical use or regulatory approval for the imagabalin + lithium combination exists, analogous gabapentinoid-lithium combinations may have additive effects but also present increased risks of central nervous system depression, including drowsiness, confusion, dizziness, and impaired psychomotor function[1][2].
- Other names
- imagabalin + lithium
02
Targets
α2δ (Voltage-gated calcium channel alpha-2-delta subunit)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)IMPA1 (Inositol Monophosphatase)GSK3 (Glycogen synthase kinase 3 beta)
Beyond the preview
Go deeper on imagabalin + lithium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imagabalin + lithium.